NCT07583251 · Phase 1 · RECRUITING
Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
This trial tests whether an oral supplement called gamma-glutamylcysteine, a building block the body uses to make the antioxidant glutathione, is safe and well tolerated. People with mild cognitive impairment take 400, 800, or 1200 mg daily for three months. It is a Phase 1 trial, an early check on safety, not proof it works.
You may qualify if
- Memory complaints;
- MCI diagnosis
- MoCA score between 18-25
- Age 55 - 80 years old.
- Ability to read and write in English
You're excluded if
- Subjects with a history of cancer;
- Subjects with a history of schizophrenia, manic-depressive disorder
- Subjects on antioxidant therapy (ashwagandha, gingko biloba, N-acetylcysteine or glutathione)
- Subjects on illicit drug (cocaine, heroin, marijuana, or fentanyl) abuse/dependence;
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-08-07